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REPLACEMENT METHODS AND ADVANCES 
IN BIOMEDICAL RESEARCH
Replacement methods are usually defined as methods 
which permit a given purpose to be achieved without 
conducting experiments or other scientific procedures 
on animals according to the 3Rs Declaration of Bolo-
gna from 1999. It is currently well accepted that more 
than one method is necessary to allow the full replace-
ment of an animal experimentation. These so-called 
partial replacement methods are considered to be alter-
native methods that can partially replace an animal ex-
periment, but requires the use of additional alternative 
methods as part of a strategy approach for achieving full 
replacement of the animal test [1].
The definition of a replacement method has consid-
erable evolved from the original definition of Replace-
ment by Russel and Burch from 1959, who considered 
for example that an experiment performed on an anaes-
thetised animal, which is killed under the anaesthetic at 
the end of the experiment, was a Replacement method. 
More recently, the NC3Rs has defined replacement 
methods as “accelerating the development and use 
of models and tools, based on the latest science and 
technologies, to address important scientific questions 
without the use of animals” (www.nc3rs.org.uk/the-3rs). 
The Swiss 3RCC in counterpart defines replacement 
methods as full or partial replacement methodologies, 
that are based on e.g., cultured cells (including primary 
cells), tissues and organs as well as the use of testing 
strategies that take into account existing in vivo data, in 
vitro methods, in silico/computational methods, physi-
cochemical properties and non-testing data (https://
swiss3rcc.org/2018/05/02/what-are-the-3-r).
Latest advances in biomedical research and bioengi-
neering provide a major opportunity to achieve more 
physiologically-relevant human models. Their use with-
in integrated strategies, combined with the knowledge 
of the underlying biological process, can contribute to a 
more mechanistic and predictive human science whilst 
decreasing the animal studies that may be necessary. 
Sistare et al. [2] report that the increasingly sophisti-
cated in vitro humanized test systems, emerging com-
putational models and novel translations biomarkers 
are being used to improve the ability to better predict 
drug induced liver injury, and make the development of 
safer drug candidates less dependent on animal stud-
ies. Malloy et al. [3] highlights the usefulness of using 
predictive approaches based on e.g. in silico and in vitro 
approaches, computational models, to help assessing 
the safety of chemicals.
A study conducted on the application of 3Rs in 
toxicological research in the pharmaceutical industry, 
showed that there are existing synergies between all 
the 3Rs, and in particular that in silico, in vitro and in 
vivo methods all hold the potential to contribute to the 
reduction of animal use [4]. Furthermore, Wolfensohn 
Address for correspondence: Chantra Eskes, Swiss 3R Competence Centre, Hocheschulstrasse 6, 3012 Bern, Switzerland.  
E-mail: chantra.eskes@swiss3rcc.org.
Key words
•  Integrated strategy 
approaches
• IATA
• DAs
• AOPs
Abstract
It is currently well accepted that in general, more than one method is necessary to al-
low the full replacement of an animal experimentation. These so called partial replace-
ment methods can be used within integrated strategy approaches that combine different 
methods and information sources. A number of integrated strategy approaches were 
implemented within recent years in different areas of safety and regulatory toxicology. 
Moreover, latest advances in biomedical research and bioengineering provide a major 
opportunity to make use of in vitro human-based and/or three-dimensional complex 
models that can contribute to achieve more physiologically-relevant models. Examples 
herein describe currently existing integrated strategy frameworks aiming at full or partial 
replacement purposes and/or at gaining mechanistic insights. Furthermore, a general 
concept is provided on how 3R methods might be integrated in a strategy approach in 
order to ensure that animal experimentation is conducted only as a last resort.
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[5] showed that the collaborative multicentre research 
projects within the framework of the European Innova-
tive Medicines Initiative (IMI) research programme can 
reduce the dependence on animal use in areas where it 
has normally been viewed as necessary. In particular, 
the collaborative platforms enabled the 3Rs to be ad-
dressed and optimized on multiple different levels, such 
as the selection of models to be tested, the protocols to 
be followed and the interpretation of results generated, 
leading to an overall reduction in the use of laboratory 
animals.
Finally, Piersma et al. [6] suggest that a transition 
to a mechanistically-based human-focused safety as-
sessment is needed, which steps away from the tradi-
tional animal studies, and defines human biology as a 
new standard. However, further research is necessary to 
overcome the still existing gaps in scientific knowledge 
and technological limitations [7]. 
TESTING STRATEGY APPROACHES
The first concepts of using integrated approaches 
for the regulatory safety assessment of chemicals were 
developed already back in the late 90s and 2000s [8]. 
Recently, a transformation of the current way of con-
ducting testing calls for the use of pathway-based ap-
proaches that capture the current understanding and 
the physiological mechanisms underlying toxicity [8]. 
Testing strategy approaches represent a logical manner 
to combine pathway-based and mechanistic assays and 
information sources [9]. In recent years, the systematic 
combination of several information sources has been 
implemented in several areas of regulatory and basic 
toxicology. Different types of strategy approaches may 
be used for regulatory and toxicology purposes as de-
scribed here below:
• Integrated Approaches for Testing and Assessment 
(IATA) may allow for full and/or partial replacement 
of animal testing as recommended for e.g. the assess-
ment of skin irritation & corrosion and ocular hazard. 
An IATA is defined as an approach based on mul-
tiple information sources that integrates and weights 
all relevant existing evidence and guides the targeted 
generation of new data, where required, to inform 
regulatory decision-making regarding potential haz-
ard and/or risk (OECD GD255, www.oecd.org/env/
ehs/testing/series-testing-assessment-publications-
number.htm). An IATA necessarily includes a degree 
of expert judgement, for example, in the choice of 
information sources and their weighting. Neverthe-
less, some of the IATA components, such as Defined 
Approaches to Testing and Assessment (see below), 
can be standardised (i.e. rule-based);
• Defined Approaches for Testing and Assessment 
(DAs) permit to derive a prediction that may be used 
on its own if they are deemed to be fit-for-purpose or 
considered together with other sources of informa-
tion in the context of IATA to contribute to a regula-
tory decision. A number of DAs have been proposed 
for example for the assessment of skin sensitization. 
A defined approach consists of a fixed data interpre-
tation procedure (DIP) (e.g. statistical, mathematical 
models) applied to data (e.g. in silico predictions, in 
chemico, in vitro data) generated with a defined set of 
information sources to derive a prediction (OECD 
GD255). In contrast to the assessment process with-
in IATA, that necessarily involves some degree of ex-
pert judgment, predictions generated with defined 
approaches are rule-based;
• Adverse Outcome Pathways (AOPs) are based on 
mechanistic information and may contributes to a 
regulatory decision. An AOP describes a sequence 
of events commencing with initial interaction(s) of a 
stressor with a biomolecule within an organism that 
causes a perturbation in its biology (i.e., molecular 
initiating event, MIE), which can progress through 
a dependent series of intermediate key events (KEs) 
and culminate in an adverse outcome (AO) consid-
ered relevant to risk assessment or regulatory deci-
sion-making (OECD GD233, AOPWiki, https://aop-
wiki.org). 
Although a clear-cut framework such as those exist-
ing for regulatory purposes does not exist in basic and 
biomedical research, if the combination of different in-
formation sources to study a certain mechanism and/or 
effect is a part of good scientific practices. When mak-
ing a survey about the current gaps and opportunities 
for implementing the 3Rs in Switzerland it was found 
out that most researchers are using more than one ap-
proach in parallel, combining the use of non-animal and 
animal procedures (3RCC, personal communication). 
A total of 88% of the 103 respondents using in vitro 
models use them in combination with other approaches 
and 67% of responders work occasionally or frequently 
with animals. The survey was answered by a total of 
176 Swiss respondents coming from academia (69%), 
non-profit organisations (13%), industry (10%), hospi-
tal/clinics (5%) and government or regulatory agencies 
(4%).
INTEGRATED APPROACHES FOR TESTING 
AND ASSESSMENT 
As reported by Eskes and Hofmann [10], for assess-
ing the skin irritation and corrosion of chemicals, cur-
rent internationally agreed approaches recommend the 
use of an IATA adopted as OECD Guidance Docu-
ment 203 (OECD GD203). The IATA allows to re-
place or minimize, to the extent possible, the use of 
in vivo animal testing whilst ensuring human safety. It 
comprises in a sequential way: i) the use of existing in 
vivo and in vitro information, physico-chemical proper-
ties and non-testing methods; ii) a weight-of-evidence 
evaluation of the existing data and iii) if needed, the 
conduct of prospective testing. Although no single in 
vitro test method can cover the full range of skin corro-
sion and irritation responses observed in the traditional 
in vivo Draize rabbit test, the currently validated and 
adopted in vitro methods for skin irritation and corro-
sion can replace the in vivo test when combined within 
this recommended IATA. In particular, in Europe this 
IATA represents a full replacement of the animal test-
ing as the regulatory adopted in vitro test methods can 
be used to distinguish non-classified chemicals. Animal 
testing is then conducted only when there is a need to 
satisfy other specific regulatory requirements, or when 
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the test chemical cannot be tested with the in vitro test 
methods currently adopted due to limitations or non-
applicability. 
In the area of eye irritation and serious damage, a 
number of in vitro test methods have been regulatory 
accepted for the identification of substances and mix-
tures that i) require classification for serious eye dam-
age and ii) do not require classification for eye haz-
ard effects [7]. However, there is currently no in vitro 
test method accepted for the identification of eye ir-
ritation, situated in the middle range of ocular hazard. 
Furthermore, although these assays may be combined 
in sequential testing strategies and/or within IATA as 
recommended within the OECD GD263, such strate-
gies do not currently allow for the full replacement of 
the rabbit test for acute serious eye damage and eye 
irritation. One possible reason is that the in vitro test 
methods currently accepted to identify serious eye 
damage may not cover all mechanisms of action result-
ing in serious eye damage, including, in particular, the 
persistence of effects as observed in vivo at day 21 in 
the rabbit eye test method. This situation might lead to 
circumstances where an in vivo test method may need 
to be used as a last resort, in particular since persis-
tence of tissue effects has been shown to be an impor-
tant driver for the in vivo classification of serious eye 
damage. 
The use of IATA and testing strategies have also been 
suggested for evaluating the carcinogenic potential of 
chemicals [7]. For the regulatory assessment of geno-
toxic effects of chemicals the use of a tiered testing 
strategy based on two in vitro assays is usually recom-
mended. Carcinogenicity is then assessed based on a 
combination of genotoxicity study package and a two-
year carcinogenicity study conducted in rats and mice. 
An IATA has been proposed to predict genotoxic carci-
nogenicity with high performance when using predic-
tions falling within the model’s applicability domain. 
For the non-genotoxic carcinogens an OECD expert 
working group is currently reviewing and assessing rel-
evant in vitro assays with the aim of tentatively organise 
them into levels of testing, following an Adverse Out-
come Pathway format, and examine how an IATA could 
be developed to assist regulators.
AOPs AND DAs FOR THE ASSESSMENT  
OF SKIN SENSITISATION 
There is general agreement regarding the key bio-
logical events underlying skin sensitisation. The existing 
knowledge of the chemical and biological mechanisms 
associated with skin sensitisation has been summarised 
in the form of an AOP (OECD GD168), going from 
the molecular initiating event through the intermedi-
ate events up to the adverse health effect, i.e. allergic 
contact dermatitis in humans or contact hypersensitiv-
ity in rodents. The molecular initiating event (MIE) is 
the covalent binding of electrophilic substances to nu-
cleophilic centres in skin proteins. The second key event 
(KE2) in this AOP takes place in the keratinocytes and 
includes inflammatory responses as well as gene expres-
sion associated with specific cell signalling pathways. 
The third key event (KE3) is the activation of dendritic 
cells, typically assessed by expression of specific cell 
surface markers, chemokines and cytokines. The fourth 
key event (KE4) is T-cell proliferation, which is indi-
rectly assessed in the murine Local Lymph Node Assay 
(OECD TG429). 
Three non-animal OECD Test Guidelines have been 
adopted addressing either the MIE, KE2 or KE3, and 
have used as a basis for developing IATAs and DAs. 
These approaches are mechanism-based, since they 
combine results from multiple test methods and/or 
computational tools that address different KEs of the 
AOP to assess the skin sensitization potential and in 
some cases potency of tested chemicals [11]. 
In particular, a number DAs and an IATA have been 
proposed for the purpose of skin sensitisation hazard 
assessment, potency categorization and risk assessment 
(OECD GD255 and GD256). These DAs not only vary 
in relation to the set of information sources used but 
also differ in the data interpretation procedures applied 
for converting the input data into a final prediction 
[12]. However, the data interpretation procedures have 
a common denominator that they are rule‐based and do 
not require expert knowledge to derive a prediction, in 
contrast to an IATA. With a view to support the evalu-
ation of integrated approaches in regulatory decision‐
making for skin sensitisation, the OECD is currently 
conducting a consistent and independent evaluation of 
the proposed DAs for skin sensitization. Human data, 
when available, and the LLNA as the only animal-based 
test that underwent formal validation, are generally 
used as reference for the assessment of animal-free test 
methods for skin sensitisation [13].
AOPs AND MECHANISTIC ONTOLOGY-
DRIVEN STRATEGIES 
The concept of adverse outcome pathways has also 
been applied within the US EPA’s endocrine disruptor 
screening program. AOP has been used together with 
toxicity pathway frameworks to organize and integrate 
diverse biological data for evaluating the endocrine ac-
tivity of chemicals [14]. The use of these frameworks 
allowed to establish biologically plausible links between 
endocrine mechanisms and apical responses when 
those endpoints are not measured in the same assay. 
The pathway frameworks facilitate a weight of evidence 
determination of a chemical’s potential endocrine ac-
tivity, identify data gaps, aid study design, direct assay 
development and guide testing strategies. The authors 
conclude that a variety of biological systems affect api-
cal endpoints used in regulatory risk assessments, and 
without mechanistic data, an endocrine mode of action 
cannot be determined [14]. Furthermore, AOPs are 
proposed to reduce the reliance on long-term and costly 
fish early life-stage tests required for assessing the haz-
ard of chemicals [15]. 
More recently, a mode-of-action ontology model for 
the evaluation of repeated dose toxicity of chemicals, 
has been proposed [16]. The authors report that a criti-
cal aspect in using non-animal approaches to assess the 
safety of chemicals is the challenge linked to the ca-
pacity to cover a comprehensive set of interdependent 
mechanisms of action, link them to adverse effects and 
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interpret their probability to be triggered in the light of 
the exposure to the chemical in question. Based on this, 
the authors propose critical elements and ways of estab-
lishing a mode-of-action ontology model to support the 
animal-free safety evaluation of chemicals.
Similarly, the use of an ontology-driven animal-free 
testing strategy has been proposed for developmental 
neurotoxicity testing, as a conceptual approach for de-
signing testing strategies that cover the integral mecha-
nistic landscape of developmental neurotoxicity [17]. 
Validation of these models require the coverage of the 
biological domain, rather than the classical predictive 
value of individual tests. The challenge is in mining 
modern biology, toxicology and chemical information 
to feed intelligent designs, which will define testing 
strategies for neurodevelopmental toxicity testing.
STRATEGY APPROACHES FOR 
NANOMATERIALS AND MEDICAL DEVICES 
Due to the novel physicochemical properties of nano-
materials that are related to surface characteristics, the 
approach toward toxicity test development has distinct 
considerations from traditional chemicals and requires 
adaption of the existing approaches. Examples of strat-
egies proposed for nanomaterials exist addressing the 
advantages and disadvantages of in vitro, ex vivo and in 
silico methods [18]. The authors also identify knowledge 
gaps for improving experimental and strategy design, 
highlighting the need to represent realistic exposure 
scenarios and to consider nanomaterials-specific con-
cerns such as characterization, assay interferences and 
standardization. 
In contrast, the US FDA/CDRH, discusses scientific 
principles, methods and endpoints for the replacement 
of conventional rodent testing by the inclusion and in-
tegration of clinical, diagnostic and pathologic data ob-
tained from well-designed large animal studies. The rec-
ommendations include consideration for study designs 
that utilize methods for an overall more comprehensive 
interrogation of animal systems [19].
CONCLUSION
The progresses made in modern biology and bioen-
gineering, call for a reconsideration on how to inves-
tigate and study the biological mechanisms that may 
lead to hazard effects, diseases, or to investigate the 
safety and efficacy of drugs. Figure 1 depicts a diagram, 
which takes into account the currently existing strat-
egy approaches developed for regulatory purposes, and 
summarises the main steps that are usually undertaken 
based on the 3Rs Principle. The suggested steps within 
the diagram are not meant to be a prescriptive order. 
It is hoped that the above described examples of in-
tegrated strategy approaches used within the area of 
regulatory toxicology together with the overview given 
in Figure 1 can contribute to other areas as to continue 
to promote the replacement, reduction and refinement 
of animal experimentation and ensure that animal pro-
cedures are used only as a last resort.
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